Matt Donne retweeted
bio foundation models trained on real human data
@NOETIK_ai
📁 Dario Amodei, CEO of Anthropic, says the real AI moats will not be in apps, but in medicine and the physical world.
Anyone can build on top of a model. Very few can navigate biology, regulation and real world complexity.
The biggest AI companies may not be addictive software, but systems that quietly extend human life.
Matt Donne retweeted
The fact that this beach is empty on an 80 degree day is a sign of how locked in SF is
Matt Donne retweeted
Excited for all the #SFTechWeek festivities!
Our team is hosting and attending a bunch of great events throughout the week.
Reach out to your SVB contact or head over to our Tech Week site to learn more: bit.svb.com/46AZ7Fh
Matt Donne retweeted
Immigrant scientist
Matt Donne retweeted
Let’s gooo!!!! Congrats Alan 🎉
communitymorgue.com/p/from-c…
a touch more personal
I think it’s pretty funny chatGPT put strategy next to the garbage can… #biotech #lifescience #strategy
1
279
Matt Donne retweeted
Proud to have this important work and data publicly explorable on Spring’s platform
🚨 New research from the Taipale Lab @mike_tilapia reveals that protein mislocalization impacts 1/6 of all pathogenic missense variants! 🧬 This study offers new insights into the molecular roots of genetic disorders.
📊 Data now available on the Spring Science platform! 🧵
Matt Donne retweeted
Two people today have told me that my shirt (which I like) looks like something out of the Sopranos (which I also liked). So I figured I'd post my favorite Tony Soprano quote today:
“It’s good to be in something from the ground floor. I came too late for that and I know..."
Matt Donne retweeted
Hear insights from our Senior Director, Will Van Trump, as he explores AI's transformative role in imaging.
Stay tuned for more on cell painting, analysis challenges, and how we're leading AI-driven research.
Watch Will’s talk here: buff.ly/4cBHSon
#AIinDrugDiscovery
Matt Donne retweeted
If AI completely redesigned a cell, would it constitute a new form of life?
The @arcinstitute’s @pdhsu asked that tantalizing question at #statbreakthrough last week.
Matt Donne retweeted
It's #machinelearningmonday, and today we're highlighting our 2023 SLAS poster focused on using #highcontentimaging and #machinelearning to categorize compounds into novel inflammasome inhibitor classes.
Check it out here: buff.ly/4bKoMwj
Come join our next hike partiful.com/e/bGMULSE8ZarqU…
5
244
Matt Donne retweeted
Are you looking for rare phenotypes or events in your imaging data?
A benefit of unsupervised single cell clustering is that results are driven by the data, not by a biased prior assumption. With PhenoFinder, you can identify unique phenotypes and how they're driving responses.
Matt Donne retweeted
It's been two decades since the field has demonstrated it can make mice live to the human equivalent of 130 years old. How close are we to doing the same in humans?
20 years ago, scientists figured out how to make mice live 150% longer by altering one singular gene. What have we learned since this groundbreaking discovery?
In our debut video, @alexkesin seeks to find out.
Matt Donne retweeted
Folks about to graduate with bioinformatics/data science backgrounds who are interested in research, please apply: aprecruit.ucsf.edu/JPF04398
Matt Donne retweeted
Had fun sharing more about Spring on @shanselman’s podcast.
Scott has been an inspiration of mine and a guide through T1d tech for many years — glad we finally did this.
hanselminutes.com/929/ai-sup…
Matt Donne retweeted
Did you miss your chance to talk to Spring's Head of Lab Ops, Will yesterday at his presentation? Stop by his poster #1218-C in the Data Science and AI Track this afternoon!
See more of Spring @SLAS_org : hubs.ly/Q02h6pwY0
#SpringScience #SLAS2024
Matt Donne retweeted
Today we should celebrate the perseverance of $VRTX in translating the incredible human genetics of Nav 1.8 for pain into a drug with Phaase 3 data ready for approval. The commercial market can debate the differentiation and merits vs existing generics, but it should be a huge celebration for novel science and the value of the genetic validation of targets in drug discovery - which instills the confidence in expensive, long-term, multi-candidate R&D programs against these genetic targets.